Akero Therapeutics surges as fatty liver drug reduces scarring in trial

Akero Therapeutics

04/03/2024 11:24

** Shares of drug developer Akero Therapeutics  AKRO.O  rise
89% to $52.55 premarket
    ** Company says its lead experimental drug to treat MASH, a
type of fatty liver disease, reduced scarring in patients' organ
after 96 weeks, meeting the main goal of a mid-stage study
    ** MASH, or metabolic dysfunction-associated
steatohepatitis, affects around 5% of the U.S. population
    ** Up to last close, stock down 41.6% in the last 12 months

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))